Acumen Pharmaceuticals, Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2022 Annual Meeting of Stockholders held by Acumen Pharmaceuticals, Inc. on June 15, 2022. The company is incorporated in Delaware and its common stock trades on The Nasdaq Global Select Market under the symbol ABOS.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Of the 40,496,512 shares outstanding, 34,703,319.92 shares (approximately 85.69%) were present or represented by proxy. There were 5,658,008.00 broker non-votes.
Proposal 1: Election of Class I Directors
All three nominees were elected to serve until the 2025 annual meeting.
| Name | Votes For | Votes Withheld |
|---|---|---|
| Kimberlee C. Drapkin | 28,991,354.73 | 53,957.18 |
| Jeffrey Ives, Ph.D. | 28,513,555.73 | 531,756.18 |
| Sean Stalfort | 28,322,074.00 | 723,237.91 |
Proposal 2: Ratification of Auditors
Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
| Proposal | Votes For | Votes Against | Abstained |
|---|---|---|---|
| Ratification of Ernst & Young LLP | 34,702,393.73 | 761.18 | 165.00 |
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the total number of shares outstanding (40,496,512) and the percentage of shares represented at the meeting (85.69%).
- Confirm the election of the three Class I directors: Kimberlee C. Drapkin, Jeffrey Ives, Ph.D., and Sean Stalfort.
- Note the significant number of broker non-votes (5,658,008.00) regarding the director election.
- Confirm the ratification of Ernst & Young LLP as the independent auditor for fiscal year 2022.